Fennec Pharmaceuticals Inc. (TSX: FRX)
Canada
· Delayed Price · Currency is CAD
7.35
+0.76 (11.53%)
Nov 22, 2024, 3:47 PM EST
Fennec Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 40.32 | 13.27 | 23.77 | 21.1 | 30.34 | 13.65 | Upgrade
|
Cash & Short-Term Investments | 40.32 | 13.27 | 23.77 | 21.1 | 30.34 | 13.65 | Upgrade
|
Cash Growth | 225.19% | -44.19% | 12.67% | -30.46% | 122.30% | -40.08% | Upgrade
|
Receivables | 12.91 | 8.81 | 1.55 | - | - | - | Upgrade
|
Inventory | 1.13 | 2.16 | 0.58 | - | - | - | Upgrade
|
Prepaid Expenses | 3.07 | 2.58 | 0.77 | 1.03 | 0.8 | 0.23 | Upgrade
|
Other Current Assets | 0.55 | 0.04 | 0.06 | 0.25 | 0.28 | 0.01 | Upgrade
|
Total Current Assets | 57.97 | 26.86 | 26.73 | 22.39 | 31.42 | 13.88 | Upgrade
|
Long-Term Deferred Charges | 0.96 | 0.01 | 0.21 | 0.03 | - | 0.26 | Upgrade
|
Total Assets | 58.92 | 26.86 | 26.94 | 22.41 | 31.42 | 14.15 | Upgrade
|
Accounts Payable | 3.87 | 3.78 | 2.39 | 0.78 | 1.57 | 1.61 | Upgrade
|
Accrued Expenses | 3.31 | 3.75 | 2.22 | 0.88 | 0.78 | 0.66 | Upgrade
|
Current Portion of Leases | 0.01 | 0.02 | - | - | - | - | Upgrade
|
Total Current Liabilities | 7.44 | 7.55 | 4.61 | 1.65 | 2.35 | 2.27 | Upgrade
|
Long-Term Debt | 32.1 | 30.93 | 24.9 | 4.99 | - | - | Upgrade
|
Long-Term Leases | - | 0 | - | - | - | - | Upgrade
|
Total Liabilities | 64.09 | 38.49 | 29.51 | 6.64 | 2.35 | 2.27 | Upgrade
|
Common Stock | 145.44 | 144.31 | 142.59 | 140.8 | 140.73 | 106.39 | Upgrade
|
Additional Paid-In Capital | 65.84 | 62.07 | 56.8 | 53.21 | 49.23 | 48.27 | Upgrade
|
Retained Earnings | -217.7 | -219.25 | -203.2 | -179.49 | -162.14 | -144.03 | Upgrade
|
Comprehensive Income & Other | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | Upgrade
|
Shareholders' Equity | -5.17 | -11.62 | -2.57 | 15.77 | 29.07 | 11.88 | Upgrade
|
Total Liabilities & Equity | 58.92 | 26.86 | 26.94 | 22.41 | 31.42 | 14.15 | Upgrade
|
Total Debt | 32.1 | 30.95 | 24.9 | 4.99 | - | - | Upgrade
|
Net Cash (Debt) | 8.22 | -17.69 | -1.13 | 16.11 | 30.34 | 13.65 | Upgrade
|
Net Cash Growth | - | - | - | -46.90% | 122.30% | -40.08% | Upgrade
|
Net Cash Per Share | 0.30 | -0.67 | -0.04 | 0.62 | 1.28 | 0.69 | Upgrade
|
Filing Date Shares Outstanding | 27.43 | 27.1 | 26.41 | 26.01 | 26 | 19.9 | Upgrade
|
Total Common Shares Outstanding | 27.42 | 27.03 | 26.36 | 26.01 | 26 | 19.9 | Upgrade
|
Working Capital | 50.53 | 19.31 | 22.12 | 20.73 | 29.07 | 11.61 | Upgrade
|
Book Value Per Share | -0.19 | -0.43 | -0.10 | 0.61 | 1.12 | 0.60 | Upgrade
|
Tangible Book Value | -5.17 | -11.62 | -2.57 | 15.77 | 29.07 | 11.88 | Upgrade
|
Tangible Book Value Per Share | -0.19 | -0.43 | -0.10 | 0.61 | 1.12 | 0.60 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.